Page last updated: 2024-10-31
activins and Froehlich's Syndrome
activins has been researched along with Froehlich's Syndrome in 3 studies
Activins: Activins are produced in the pituitary, gonads, and other tissues. By acting locally, they stimulate pituitary FSH secretion and have diverse effects on cell differentiation and embryonic development. Activins are glycoproteins that are hetero- or homodimers of INHIBIN-BETA SUBUNITS.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Treatment with leptin restores menstruation in many (60% responders) but not all (40% non-responders) women, suggesting that leptin is not the only regulator of reproductive function related to energy balance." | 5.56 | Circulating profile of Activin-Follistatin-Inhibin Axis in women with hypothalamic amenorrhea in response to leptin treatment. ( Bouzoni, E; Mantzoros, CS; Perakakis, N, 2020) |
| "Treatment with leptin restores menstruation in many (60% responders) but not all (40% non-responders) women, suggesting that leptin is not the only regulator of reproductive function related to energy balance." | 1.56 | Circulating profile of Activin-Follistatin-Inhibin Axis in women with hypothalamic amenorrhea in response to leptin treatment. ( Bouzoni, E; Mantzoros, CS; Perakakis, N, 2020) |
| "Forty women with idiopathic premature ovarian failure (POF), 23 women with hypogonadotropic hypothalamic amenorrhea, 40 healthy postmenopausal women, and 40 age-matched women with normal ovarian function (controls)." | 1.30 | Low levels of serum inhibin A and inhibin B in women with hypergonadotropic amenorrhea and evidence of high levels of activin A in women with hypothalamic amenorrhea. ( Florio, P; Genazzani, AD; Genazzani, AR; Hartmann, B; Kirchengast, S; Luisi, S; Petraglia, F; Santuz, M, 1998) |
Research
Studies (3)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
Authors
| Authors | Studies |
|---|
| Bouzoni, E | 1 |
| Perakakis, N | 1 |
| Mantzoros, CS | 1 |
| Petraglia, F | 1 |
| Hartmann, B | 1 |
| Luisi, S | 1 |
| Florio, P | 1 |
| Kirchengast, S | 1 |
| Santuz, M | 1 |
| Genazzani, AD | 1 |
| Genazzani, AR | 1 |
| Casper, FW | 1 |
| Seufert, RJ | 1 |
| Pollow, K | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Randomized, Double-blind, Placebo-controlled Trial of Human Recombinant Leptin (r-metHuLeptin) for the Treatment of Hypothalamic (Exercise-Induced) Amenorrhea[NCT00130117] | Phase 2 | 20 participants (Actual) | Interventional | 2010-04-30 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Body Composition BMI
(NCT00130117)
Timeframe: 36 weeks
| Intervention | BMI-kg/m^2 (Mean) |
|---|
| r-metHuLeptin | 20.8 |
| Placebo | 21.1 |
Body Fat
(NCT00130117)
Timeframe: 36 weeks
| Intervention | fat % (Mean) |
|---|
| r-metHuLeptin | 23.9 |
| Placebo | 20.8 |
Hip BMD
(NCT00130117)
Timeframe: 9months
| Intervention | g/cm2 (Median) |
|---|
| r-metHuLeptin | 0.89 |
| Placebo | 0.88 |
Lumbar BMD
(NCT00130117)
Timeframe: 9 months
| Intervention | g/cm2 (Median) |
|---|
| r-metHuLeptin | 0.92 |
| Placebo | 0.97 |
Radial BMD
(NCT00130117)
Timeframe: 9 months
| Intervention | g/cm2 (Median) |
|---|
| r-metHuLeptin | 0.54 |
| Placebo | 0.54 |
the Difference Between the Placebo and Leptin Treated Groups in the Change in Bone Mineral Content(BMC) at the Anteroposterior (AP) Spine From Baseline to 36 Weeks
(NCT00130117)
Timeframe: 36 weeks
| Intervention | g (Mean) |
|---|
| r-metHuLeptin | 51.0 |
| Placebo | 58.2 |
Total Body BMD
(NCT00130117)
Timeframe: 36 weeks
| Intervention | g/cm^2 (Median) |
|---|
| r-metHuLeptin | 1.07 |
| Placebo | 1.13 |
Total Body BMD
(NCT00130117)
Timeframe: 9 months
| Intervention | g/cm2 (Median) |
|---|
| r-metHuLeptin | 1.09 |
| Oral Contraceptive Pills (OCPs) | 1.13 |
Bone Markers - Ctx and Sclerostin
(NCT00130117)
Timeframe: 36 weeks
| Intervention | ng/mL (Median) |
|---|
| CTX | Sclerostin |
|---|
| r-metHuLeptin | 0.60 | 0.08 |
Other Studies
3 other studies available for activins and Froehlich's Syndrome